International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation
Generics Players Could Benefit From Greater Control Over Their Prices In 2023
Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.
You may also be interested in...
One Year On: Russia, Ukraine And The Generics Industry
On the anniversary of Russia’s invasion of Ukraine, the generics industry reflects on its contributions to relief efforts as well as the impact that the war has had on the supply chain.
German Generic Reform To Relax Pediatric Pricing
Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.
Building The Pharma Supply Chain Of The Future
The worst of COVID-19’s disruption appears to be in the pharma supply chain’s rearview mirror, but logistics stakeholders still have a number of questions to answer and challenges to overcome as they attempt to become future-proof.